CALENDAR OF REPORTING DATES FOR ARIZONA SPECIAL ELECTIONS—Continued

<table>
<thead>
<tr>
<th>Report</th>
<th>Close of books</th>
<th>Reg./Cert. and overnight mailing deadline</th>
<th>Filing deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Primary</td>
<td>02/07/18</td>
<td>02/12/18</td>
<td>02/15/18</td>
</tr>
<tr>
<td>Pre-General</td>
<td>04/04/18</td>
<td>04/09/18</td>
<td>04/12/18</td>
</tr>
<tr>
<td>April Quarterly</td>
<td>—WAIVED—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-General</td>
<td>05/14/18</td>
<td>05/24/18</td>
<td>05/24/18</td>
</tr>
<tr>
<td>July Quarterly</td>
<td>06/30/18</td>
<td>07/15/18</td>
<td>07/15/18</td>
</tr>
</tbody>
</table>

Committees Involved in Both the Special Primary (02/27/18) and Special General (04/24/18) Must File:

Committees Involved in Only the Special General (04/24/18) Must File:

On behalf of the Commission,

Steven T. Walther,
Chairman, Federal Election Commission.

[FR Doc. 2017–27363 Filed 12–19–17; 8:45 am]
BILLING CODE 6715–01–P

FEDERAL MARITIME COMMISSION

Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreements under the Shipping Act of 1984. Interested parties may submit comments on any agreements to the Secretary, Federal Maritime Commission, Washington, DC 20573, within twelve days of the date this notice appears in the Federal Register. A copy of each agreement is available through the Commission's website (www.fmc.gov) or by contacting the Office of Agreements (202) 523–5793 or tradeanalysis@fmc.gov.

Agreement No.: 011426–064.
Title: Central America Discussion Agreement.
Parties: Crowley Latin America Services, LLC; Dole Ocean Cargo Express, Great White Fleet Corp.; Great White Fleet Liner Services, Ltd.; King Ocean Services Limited, Inc.; and Seaboard Marine Ltd.
Synopsis: The amendment adds Great White Fleet Liner Service Ltd. as a single party to the agreement. The Parties request expedited review.

Agreement No.: 012212–003.
Title: NYK/Grimaldi Cooperative Working Agreement.
Synopsis: The amendment deletes Hamburg Sud as a party to the Agreement.

Rachel E. Dickon,
Assistant Secretary.

[FR Doc. 2017–27390 Filed 12–19–17; 8:45 am]
BILLING CODE 6731–AA–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and §225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than January 8, 2018.

A. Federal Reserve Bank of St. Louis (David L. Hubbard, Senior Manager)
P.O. Box 442, St. Louis, Missouri 63166–2034. Comments can also
be sent electronically to Comments.applications@stls.frb.org:

B. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 1. David Riordan, Abilene, Kansas; Robert Riordan, Solomon, Kansas; Dennis Riordan, Salina, Kansas; Michael Riordan, St. Charles, Missouri; and Kirk Berneking, Salina, Kansas; to retain voting shares of Solomon Bancshares, Inc., Solomon, Kansas, and thereby indirectly retain shares of Solomon State Bank, Solomon, Kansas.


Ann E. Misback,
Secretary of the Board.

[FR Doc. 2017–27408 Filed 12–19–17; 8:45 am]
BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting.

The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–PAR15–303, Occupational Safety and Health Education Research Centers (ERC).

Time: 8:30 a.m.–6:00 p.m., EST.
Place: The Alexandrian Hotel, 480 King Street Alexandria, VA 22314, 703–549–6680.

Agenda: The meeting will include the initial review, discussion, and evaluation of applications received in response to PAR15–303, Occupational Safety and Health Education Research Centers (ERC).

For further information contact: Michael Goldcamp, Ph.D., Scientific Review Officer/CDER, 1095 Willowdale Road, Mailstop H1808, Morgantown, West Virginia, 26505, (304) 285–5951; mgoldcamp@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office; Centers for Disease Control and Prevention.

[FR Doc. 2017–27324 Filed 12–19–17; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket No. FDA–2017–D–6380

Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases.”

FDA intends to no longer grant orphan drug designation to drugs for pediatric subpopulations of common diseases (i.e., diseases or conditions with an overall prevalence of over 200,000 in the United States), unless the use of the drug in the pediatric subpopulation meets the regulatory criteria for an orphan subset, or unless the disease in the pediatric subpopulation is considered a different disease from the disease in the adult population. This will help resolve an unintended loophole in the Pediatric Research Equity Act (PREA) orphan exemption process where a sponsor holding a pediatric-subpopulation designation can submit a marketing application for use of its drug in the non-orphan adult population of that disease, get a pediatric-subpopulation designation for the pediatric subset of the disease, and, due to this designation, be exempt from conducting the pediatric studies normally required under PREA when seeking approval of the adult indication.

DATES: Submit either electronic or written comments on the draft guidance by January 19, 2018 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submission

Submit electronic comments in the following way:

• Federal Rulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submission

Submit written/paper submissions as follows:

• Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA–2017–D–6380 for “Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.